Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botensilimab - Agenus

Next Previous
Drug Profile

Botensilimab - Agenus

Alternative Names: AGEN-1181; Anti-CTLA-4 Monoclonal Antibody AGEN1181; BOT - Agenus; Fc-enhanced CTLA-4 antibody

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; Immune Oncology Research Institute
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Solid tumours
  • Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Renal cell carcinoma

Most Recent Events

  • 03 Jun 2025 Botensilimab licensed to Zydus Lifesciences in India and Sri Lanka
  • 20 May 2025 Phase-II clinical trials in Rectal cancer (Combination therapy) in USA (IV) (NCT06780787)
  • 28 Apr 2025 Efficacy and adverse event data from the phase II/III NEOASIS trial in Solid tumours released by Agenus

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top